본문으로 건너뛰기
← 뒤로

Targeting the hepatic circadian clock concomitant with tyrosine kinase inhibition reverses late-stage hepatocellular carcinoma.

1/5 보강
Cell reports 📖 저널 OA 38.5% 2022: 1/1 OA 2024: 6/12 OA 2025: 20/55 OA 2026: 20/54 OA 2022~2026 2025 Vol.44(11) p. 116313
Retraction 확인
출처

Fekry B, Aggarwal S, Van Drunen R, Bravo R, Escalante A, Atkins C, Pan S, Chen Z, Sun K, Hall DR, Younes M, Eckel-Mahan K

📝 환자 설명용 한 줄

Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths.

이 논문을 인용하기

↓ .bib ↓ .ris
APA Fekry B, Aggarwal S, et al. (2025). Targeting the hepatic circadian clock concomitant with tyrosine kinase inhibition reverses late-stage hepatocellular carcinoma.. Cell reports, 44(11), 116313. https://doi.org/10.1016/j.celrep.2025.116313
MLA Fekry B, et al.. "Targeting the hepatic circadian clock concomitant with tyrosine kinase inhibition reverses late-stage hepatocellular carcinoma.." Cell reports, vol. 44, no. 11, 2025, pp. 116313.
PMID 41124076 ↗

Abstract

Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths. Most patients present at advanced stages, and the effectiveness of tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors is constrained by limited patient response. A subset of HCC shows elevated expression of the promoter 2 ("P2")-driven hepatocyte nuclear factor 4 alpha (HNF4α) isoform, which directly transcriptionally represses the circadian brain and muscle ARNT-like protein 1 (BMAL1) transcription factor. This subtype of HCC is robustly inhibited by the plant-based flavonoid nobiletin (NOB), a circadian-fortifying compound. Using patient-matched human HCC and serum, we show that BMAL1-deficient HCC shows exaggerated carnitine palmitoyl transferase expression and related metabolite abundance and that P2-HNF4α regulates the carnitine palmitoyl transferase I gene. Finally, using different preclinical models, we show that the anti-tumor activity of TKIs, when they are co-administered with NOB, is maximal. Our results suggest that chronotherapy and combination therapy might provide improved clinical outcomes for individuals with BMAL1-deficient HCC.

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

… 외 3개

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반